Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30327623 | 0.82 | SLC1A2 (0.41) | SLC1A2ALDH1A1LMNAKMT2AATM | |
| SCHEMBL28231228 | 0.80 | SLC1A2 (0.40) | SLC1A2ALDH1A1KMT2AATMMEN1 | |
| SCHEMBL4522866 | 0.80 | SLC1A2 (0.40) | SLC1A2ALDH1A1KMT2AATMMEN1 | |
| SCHEMBL19031828 | 0.77 | SLC1A2 (0.41) | SLC1A2ALDH1A1KMT2AATMMEN1 | |
| SCHEMBL7259853 | 0.76 | SLC1A2 (0.40) | SLC1A2ALDH1A1KMT2AATM | |
| SCHEMBL1564214 | 0.76 | KMT2A (0.53) | SLC1A2ALDH1A1KMT2AATMMEN1 | |
| SCHEMBL18020563 | 0.76 | SLC1A2 (0.45) | SLC1A2ALDH1A1LMNAKMT2AATM | |
| SCHEMBL57078 | 0.76 | KMT2A (0.53) | SLC1A2ALDH1A1KMT2AATMMEN1 | |
| SCHEMBL5165443 | 0.75 | RECQL (0.41) | PHGDHRAB9AALDH1A1LMNARECQL | |
| SCHEMBL15511368 | 0.75 | CA1 (0.41) | SLC1A2ALDH1A1LMNAKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114364393-A | Methods of treatment using G-CSF protein complexes | 光谱制药有限公司 | 2022-04-15 | — | — | CN | claimed |
| US-20200230253-A1 | CONJUGATE OF IDURONATE-2-SULFATASE | HANMl PHARM. CO., LTD. (KR) | 2020-07-23 | — | — | US | claimed |
| CN-111433221-A | Long-acting conjugates of glucagon-like peptide-2 (G L P-2) derivatives | 韩美药品株式会社 | 2020-07-17 | — | — | CN | claimed |
| EP-2963055-B1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM IND CO LTD (KR) | 2019-05-15 | — | — | EP | claimed |
| US-20160000931-A1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM. CO., LTD. (KR) | 2016-01-07 | — | — | US | claimed |
| EP-2963055-A1 | SITE-SPECIFIC INSULIN CONJUGATE | Hanmi Pharm. Co., Ltd. (KR) | 2016-01-06 | — | — | EP | claimed |
| CN-110536899-B | Insulin analogue complex with reduced affinity for insulin receptor and uses thereof | 韩美药品株式会社 | 2023-12-12 | — | — | CN | disclosed |
| CN-117157094-A | Pharmaceutical composition for preventing or treating chronic kidney disease comprising glucagon derivative | 韩美药品株式会社 | 2023-12-01 | — | — | CN | disclosed |
| US-20230330184-A1 | METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX | SPECTRUM PHARMACEUTICALS INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-116847868-A | Pharmaceutical composition comprising GIP derivative or long-acting conjugate thereof for preventing or treating pulmonary diseases | 韩美药品株式会社 | 2023-10-03 | — | — | CN | disclosed |
| US-20230270822-A1 | NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX | SPECTRUM PHARMACEUTICALS INC. (US) | 2023-08-31 | — | — | US | disclosed |
| CN-116600831-A | Triple agonists or conjugates thereof active on all of glucagon, GLP-1 and GLP receptors for the treatment of neurodegenerative diseases | 韩美药品株式会社 | 2023-08-15 | — | — | CN | disclosed |
| CN-116528885-A | Pharmaceutical composition for preventing or treating vasculitis comprising glucagon/GLP-1/GIP triple agonist or long-acting conjugate thereof | 韩美药品株式会社 | 2023-08-01 | — | — | CN | disclosed |
| CN-111433221-A | Long-acting conjugates of glucagon-like peptide-2 (G L P-2) derivatives | 韩美药品株式会社 | 2020-07-17 | — | — | CN | disclosed |
| EP-2963055-B1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM IND CO LTD (KR) | 2019-05-15 | — | — | EP | disclosed |
| US-20160000931-A1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM. CO., LTD. (KR) | 2016-01-07 | — | — | US | disclosed |
| EP-2963055-A1 | SITE-SPECIFIC INSULIN CONJUGATE | Hanmi Pharm. Co., Ltd. (KR) | 2016-01-06 | — | — | EP | disclosed |
| EP-1861125-A2 | CONJUGATES OF AN HGH MOIETY AND PEG DERIVATIVES | Nektar Therapeutics Al, Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20060233740-A1 | Conjugates of an hGH moiety and a polymer | NEKTAR THERAPEUTICS | 2006-10-19 | — | — | US | disclosed |
| WO-2006102659-A2 | CONJUGATES OF AN hGH MOIETY AND A POLYMER | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060233740-A1 | Conjugates of an hGH moiety and a polymer | GGH, NGLY1, FOLH1 | SLC1A2 722/4885PHGDH 39/4885RAB9A 3601/4885 |
| US-20200230253-A1 | CONJUGATE OF IDURONATE-2-SULFATASE | IDUA, FCGR2A, CNDP2 | SLC1A2 1274/4885PHGDH 449/4885RAB9A 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.